drugset / Trial / NCT00911092

Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer

NCT00911092

Phase 4 Completed 50 enrolled Centre Oscar Lambret
Non-randomizedSingle-groupOpen-label

Summary

The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.

Timeline

Start
2007-10
Primary completion
2011-09
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2
Subject fluorouracil Small molecule 1000 mg/m2

Indications